Bleximenib

Bleximenib (JNJ-75276617) is a small-molecule drug developed by Janssen Research & Development. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06852222 (A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukaemia (AML)), in acute myeloid leukaemia. The largest, NCT06852222, plans to enrol 600 participants with primary completion expected 2029-06-22. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.